| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.1 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.1 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |